Eupraxia Pharmaceuticals Inc.
EPRX
$7.51
-$0.07-0.92%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -51.26% | -4.09% | -7.25% | 13.65% | 9.63% |
| Total Depreciation and Amortization | 38.44% | 38.51% | 21.91% | 16.34% | 10.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 399.73% | 4,083.77% | 319.88% | 346.48% | 6.93% |
| Change in Net Operating Assets | 89.45% | 104.76% | -298.22% | -209.99% | -226.40% |
| Cash from Operations | 4.81% | 17.31% | -18.41% | -33.80% | -44.56% |
| Capital Expenditure | -465.16% | -302.47% | -450.65% | -269.49% | -41.96% |
| Sale of Property, Plant, and Equipment | -- | -97.89% | -97.89% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -683.11% | -443.81% | -775.88% | -229.26% | -2.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -0.54% | -14,078.69% | -11,408.06% |
| Issuance of Common Stock | 38.49% | 357.85% | -18.02% | -27.10% | 159.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 66.12% | 656.08% | -20.45% | -47.69% | 117.20% |
| Foreign Exchange rate Adjustments | 127.87% | -814.58% | -69.46% | -543.33% | -338.01% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 244.94% | 604.96% | -139.92% | -138.46% | 1,175.93% |